Therapeutic agent

Sirolimus (low-dose Rapamycin)

ModerateEvidence level
2Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.

Clinical Trials

2 trial(s) registered

NCT IDTitlePhaseStatus
NCT06960928Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19Phase 3Recruiting
NCT04948203Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID FibrosisPhase 2Active, not recruiting

Key Studies / References

  • See linked studies